GSK Pharmaceuticals stock: Q4 FY26 profit reached 277.86 crore rupees

Published on 11/01/2026 at 00:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

GSK Pharmaceuticals stock is in focus after the Indian drugmaker reported consolidated Q4 FY26 profit of 277.86 crore Indian rupees. The results date to May 2026.

India Pharma Results And Market Context

GlaxoSmithKline Pharmaceuticals reported consolidated Q4 FY26 profit of 277.86 crore Indian rupees on May 13, 2026.
The company is listed in India under NSE ticker GLAXO and BSE code 500660.
Investors will focus on the companys next results and operating momentum in the Indian pharmaceutical market.

GSK Pharma, INE159A01016, Illustration mit AI erstellt.

GlaxoSmithKline Pharmaceuticals reported consolidated profit of 277.86 crore Indian rupees for the fourth quarter of fiscal 2026, according to EquityBulls. The result was listed on May 13, 2026, while the company announced its Q4 and full-year results on May 14.

Profit Keeps India Business In Focus

The result gives investors a dated reference point for the Indian listed pharmaceutical business. The companys results calendar and subsequent operating updates remain important for assessing whether earnings momentum can continue beyond the March 2026 reporting period.

GlaxoSmithKline Pharmaceuticals stock is listed under NSE ticker GLAXO and BSE code 500660. EquityBulls listed a BSE close of 2,483.55 Indian rupees for October 30, 2026, with a decline of 32.10 rupees, or 1.28 percent, on that session.

For investors, the central question is how the company converts its established pharmaceutical portfolio into recurring growth in India. The May result remains an earlier reporting-period reference rather than a statement about the companys November 2026 trading performance.

Access the real-time quote of GlaxoSmithKline Pharmaceuticals stock for the latest market indication.